Overview

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to see if Leukine(R) (sargramostim) improves the effectiveness of the pneumococcal vaccine, a medicine used to prevent pneumococcal pneumonia, in patients with chronic lymphocytic leukemia (CLL).
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Bayer
Treatments:
Heptavalent Pneumococcal Conjugate Vaccine
Molgramostim
Sargramostim
Vaccines